Navigation Links
Genoptix Announces Participation at the Twentieth Annual Piper Jaffray Healthcare Conference
Date:11/25/2008

CARLSBAD, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the Twentieth Annual Piper Jaffray Healthcare Conference scheduled to take place at the New York Palace Hotel in New York City on December 2-3, 2008.

Dr. Tina S. Nova, CEO and President of Genoptix, will present at the conference on Wednesday, December 3, beginning at approximately 2:00 p.m. EST. Dr. Nova will provide an overview of the Company's specialized diagnostic laboratory service offerings, growth strategies and past operational performance.

The presentation is expected to last approximately 30 minutes, including an audience Q&A session. The presentation will be web cast live and made accessible through the investor relations section of the Genoptix website at www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. A replay will also be available for 30 days following the initial presentation web cast.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma.Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloittes 2008 Technology Fast 500
2. Genoptix Announces Participation at the BIOCOM Investor Conference 2008
3. Genoptix Announces Participation at the UBS Global Life Sciences Conference
4. Genoptix Reports Strong Financial Results For Third Quarter 2007
5. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
6. Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President
7. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
8. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
9. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
10. CorVel Announces MSA Agent Services
11. Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and i.v.Station(TM PENDING) Robots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Vilnius, Lithuania, announced today that they have entered into a multiyear collaboration to ... provide CRISPR researchers with additional tools for gene editing across all applications. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract ... to improve patient outcomes and quality of life, will now be offering its ... attributed to new regulatory requirements for all new drug products, including the finalization ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
Breaking Biology Technology:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):